An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Docetaxel and Cisplatin Every 3 Weeks in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2018
At a glance
- Drugs Ombrabulin (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 21 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Jul 2011 Planned end date changed from 1 Apr 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 19 Jan 2011 Planned End Date changed from 1 Apr 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.